Evidence map›Paper›PMID 39910422›Full record

Observational studyBMC cardiovascular disorders2025

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study.

Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yinge ZhanDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China.
Liu LiDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China.
Jie ZhouDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China.
Yishan MaDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China.
Xuchong GuanDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China.
Suo WangDepartment of Cardiovascular Medicine, Shijiazhuang People's Hospital, Shijiazhuang City, Hebei Province, China.
Ya ChangDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang City, Hebei Province, 050000, China. cardio2013@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF).

methodsA prospective observational study was conducted from May 2022 to May 2023, focusing on patients with HFrEF admitted to our hospital. Eligible patients were sequentially numbered and enrolled based on specific inclusion and exclusion criteria. They were divided into two groups: one receiving standard heart failure therapy and the other receiving standard therapy plus Vericiguat. Data were collected at baseline and at 1, 3, and 6 months post-discharge, including NT-proBNP, sST2, and echocardiographic assessments. All patients underwent CPET before discharge and again six months post-discharge for within-subject comparisons.

resultsThe study enrolled 158 patients, with 79 in each treatment arm. No significant baseline differences were observed in the Weber Functional Classification or CPET parameters. At six months, the Vericiguat group exhibited a significant reduction in patients classified as C (from 31.6 to 7.5%) and D (from 31.6 to 3.7%), with P values less than 0.05. Additionally, Vericiguat significantly improved Peak Oxygen Consumption (from 14.24 ± 6.21 to 19.03 ± 4.87 ml/kg/min) and Anaerobic Threshold (from 10.48 ± 3.82 to 13.48 ± 3.31 ml/kg/min). Compared to the standard treatment group, the Vericiguat group demonstrated significantly higher Peak Oxygen Consumption, Anaerobic Threshold, and a lower Carbon Dioxide Equivalent Slope, with P values all below 0.05.

conclusionsVericiguat safely enhances exercise tolerance, as evaluated by CPET, in high-risk patients with HFrEF.

Indexed as

Exercise ToleranceHeart FailureStroke VolumeVentricular Function, LeftAgedBiomarkersChronic DiseaseExercise TestFemaleHeterocyclic Compounds, 2-RingHumansMaleMiddle AgedProspective StudiesPyrimidinesRecovery of FunctionBiomarkersHeterocyclic Compounds, 2-RingPyrimidinesvericiguatCardiopulmonary exercise testingHeart failure with reduced ejection fractionVericiguat

Identifiers

PMID39910422
PMCPMC11796121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.